Evidence map›Paper›PMID 22674057›Full record

ArticleCancer immunology, immunotherapy : CII2012

Cellular and cytokine-dependent immunosuppressive mechanisms of grm1-transgenic murine melanoma.

Miriam Alb, Christopher Sie, Christian Adam, Suzie Chen, Jürgen C Becker, David Schrama

Open access · hybridAbstract read
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Overcoming Immune Evasion in Melanoma.International journal of molecular sciences · 2020
    Review
  5. Article
  6. The lymph node pre-metastatic niche.Journal of molecular medicine (Berlin, Germany) · 2015
    Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Miriam AlbDepartment of Dermatology, University Hospital of Würzburg, Würzburg, Germany. miriam.alb@gmx.de
Christopher Sie
Christian Adam
Suzie Chen
Jürgen C Becker
David Schrama
Medical University of Graz · ATUniversitätsklinikum Würzburg · DERutgers, The State University of New Jersey · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Grm1-transgenic mice spontaneously develop cutaneous melanoma. This model allowed us to scrutinize the generic immune responses over the course of melanoma development. To this end, lymphocytes obtained from spleens, unrelated lymph nodes and tumor-draining lymph nodes of mice with no evidence of disease, and low or high tumor burden were analyzed ex vivo and in vitro. Thereby, we could demonstrate an increase in the number of activated CD4(+) and CD8(+) lymphocytes in the respective organs with increasing tumor burden. However, mainly CD4(+) T cells, which could constitute both T helper as well as immunosuppressive regulatory T cells, but not CD8(+) T cells, expressed activation markers upon in vitro stimulation when obtained from tumor-bearing mice. Interestingly, these cells from tumor-burdened animals were also functionally hampered in their proliferative response even when subjected to strong in vitro stimulation. Further analyses revealed that the increased frequency of regulatory T cells in tumor-bearing mice is an early event present in all lymphoid organs. Additionally, expression of the immunosuppressive cytokines TGF-β1 and IL-10 became more evident with increased tumor burden. Notably, TGF-β1 is strongly expressed in both the tumor and the tumor-draining lymph node, whereas IL-10 expression is more pronounced in the lymph node, suggesting a more complex regulation of IL-10. Thus, similar to the situation in melanoma patients, both cytokines as well as cellular immune escape mechanisms seem to contribute to the observed immunosuppressed state of tumor-bearing grm1-transgenic mice, suggesting that this model is suitable for preclinical testing of immunomodulatory therapeutics.

Indexed as

AnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell ProliferationImmunosuppressive AgentsInterleukin-10Lymph NodesLymphocyte ActivationMelanoma, ExperimentalMiceMice, Inbred C57BLMice, TransgenicMitogensReceptors, Metabotropic GlutamateRNA, MessengerT-Lymphocytes, Helper-InducerImmunosuppressive AgentsInterleukin-10metabotropic glutamate receptor type 1MitogensReceptors, Metabotropic GlutamateRNA, MessengerTransforming Growth Factor beta1

Identifiers

PMID22674057
PMCPMC3506202
OpenAlexW2039155569

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.